Clinical Trials Logo

Clinical Trial Summary

The goal of this study is to characterize tau kinetics and tau aggregation in the human CNS and to test the hypothesis that tau kinetics are altered (i.e. increased production, decreased clearance, and increased aggregation rate) in tauopathies.


Clinical Trial Description

Tauopathies are neurodegenerative diseases with tau pathology. These tauopathies are the most common pathology in neurodegenerative diseases, and they are reaching epidemic proportions. The rates of tau kinetics are central to understanding normal and abnormal processing and production and clearance of tau kinetics in humans to help understand the causes of tauopathy and evaluate tau-targeted therapeutics. This study will utilize the Stable Isotope Labeling Kinetics (SILK) method to elucidate tau kinetics in vivo in the human central nervous system (CNS) and its alteration in tauopathies. A total of ~34 participants from 3 different neurodegenerative diseases: Frontotemporal Dementia (FTD), Corticobasal Degeneration (CBD), and Progressive Supranuclear Palsy (PSP), will be invited to enroll in the study. Participants will be labeled with stable isotopes via 16hr intravenous infusion and CSF samples collected during subsequent lumbar puncture visits over ~120 days. CSF will be analyzed over time for the quantitation of labeled tau. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03545126
Study type Observational
Source Washington University School of Medicine
Contact
Status Completed
Phase
Start date August 21, 2017
Completion date March 4, 2022

See also
  Status Clinical Trial Phase
Completed NCT02365922 - Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)
Recruiting NCT03030586 - ADDIA Proof-of-Performance Clinical Study
Recruiting NCT02778607 - PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UK
Completed NCT02531360 - Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies Phase 0
Completed NCT02133846 - Safety Study of TPI-287 to Treat CBS and PSP Phase 1
Recruiting NCT04363684 - ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
Completed NCT04193527 - A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients Phase 3
Completed NCT02839642 - Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy Phase 3
Terminated NCT03391765 - An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) Phase 2
Active, not recruiting NCT02966145 - 4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2
Completed NCT02103894 - Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects Phase 1
Active, not recruiting NCT04539041 - Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy Phase 1
Completed NCT01888185 - Identifying Biomarkers of Parkinson's Disease Using Magnetic Resonance Imaging (MRI)
Completed NCT03413319 - Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 Phase 1